Abstract

M. Agouzal*, A. Quyou, K. Benchekroune and M. Khattab

The study aims to give a general idea about the experience of chelating drugs among beta-thalassemia patients in Morocco. It is a declarative survey. It was done in the therapy center of Morocco. Statistics were done in the laboratory of biological essays in Kenitra. All economic and pharmacological data were given by Novartis. Sample size was 108.78% of patients attending the service regularly take deferiprone as treatment while 8% of them combine deferiprone and deferoxamine. Most of the patients take treatments regularly. Chelators have reduced mortality. They have induced skin lightening for 26% of the patients in Rabat. Patients taking deferoxamine experienced injection site reactions. Most of adverse drug reactions (ADR) due to deferiprone were digestive. The main problem with chelators in Morocco is lack of accessibility to drugs, that’s why the therapy center of Rabat has worked hard in collaboration with an Italian project to resolve the problem.